Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases

调节大脑特异性胆固醇羟化酶 Cyp46A1 作为治疗朊病毒疾病的新方法

• 批准号: 454456
• 负责人: Ali Tahir
• 金额: $ 3.28万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-10-01 至 2022-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=454456&lang=en
• 关键词: Brain Cholesterol Metabolism; Cellular Models Of Prion Diseases; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Fda-Approved Repurposed Drug (Efavirenz); Human Prion Diseases; Mouse Models Of Human Prion Diseases; Neurodegenerative D

Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease, which has

朊病毒病是影响人类和动物的传染性和致命的神经退行性疾病。克雅氏病（Creutzfeldt-Jakob disease，CJD）是人类最常见的朊病毒病。动物朊病毒疾病包括绵羊/山羊瘙痒症和疯牛病，